ライフサイエンスコーパス: endomyocardial biopsy

1 e, proven with positive bone scintigraphy or endomyocardial biopsy).

2 oronary computed tomography angiography, and endomyocardial biopsies).

3 cally, the diagnosis of myocarditis required endomyocardial biopsy.

4 en shown to correlate with the results of an endomyocardial biopsy.

5 the standard method of tissue histology from endomyocardial biopsy.

6 Nine patients underwent endomyocardial biopsy.

7 and serial echocardiography; five underwent endomyocardial biopsy.

8 gs in the diagnosis of amyloidosis proven by endomyocardial biopsy.

9 assessed by the rejection grade on the first endomyocardial biopsy.

10 osis on the basis of clinical evaluation and endomyocardial biopsy.

11 of MMF trough level at the time of scheduled endomyocardial biopsy.

12 c transplants revolves around the use of the endomyocardial biopsy.

13 DSE at the time of their regularly scheduled endomyocardial biopsy.

14 lantation at the time of serial surveillance endomyocardial biopsy.

15 uded, of whom 142 underwent TTE before first endomyocardial biopsy.

16 asive coronary angiography, cardiac MRI, and endomyocardial biopsy.

17 nical signs and symptoms and low accuracy of endomyocardial biopsy.

18 highly selected cases undergoing autopsy or endomyocardial biopsy.

19 owed positive dd-cfDNA results with negative endomyocardial biopsy.

20 ts without evidence of rejection observed on endomyocardial biopsy.

21 ntify clinically relevant non-HLA from donor endomyocardial biopsy.

22 ransplantation (ISHLT) grade 2R or higher at endomyocardial biopsy.

23 ic work-up, including genetic evaluation and endomyocardial biopsy.

24 ditis was defined by ongoing inflammation on endomyocardial biopsy.

25 Twenty-eight (88%) patients underwent endomyocardial biopsy.

26 ars) had undergone diagnostic cardiac MR and endomyocardial biopsy.

27 mic myocardial (18)F-NOS PET/CT, followed by endomyocardial biopsy.

28 nd immunoglobulins) and microvasculopathy in endomyocardial biopsy.

29 onresponse to CRT in patients with DCM using endomyocardial biopsies.

30 in human atrial tissue and right ventricular endomyocardial biopsies.

31 Egr-1 mRNA expression and rejection grade in endomyocardial biopsies.

32 men was used, and rejection was monitored by endomyocardial biopsies.

33 nd arteriolar endothelial ICAM-1 in matching endomyocardial biopsies.

34 were measured in 186 patients undergoing 365 endomyocardial biopsies.

35 187 adult HTx patients with contemporaneous endomyocardial biopsies.

36 not predominantly lymphocytic myocarditis in endomyocardial biopsies.

37 expression by sequencing RNA extracted from endomyocardial biopsies.

38 ilure and rejection and may undergo repeated endomyocardial biopsies.

39 ents could obviate the need for surveillance endomyocardial biopsies.

40 patients who were monitored with the use of endomyocardial biopsies (0.5 vs. 3.0, P<0.001).

41 After a low-grade endomyocardial biopsy (0 or 1A), one or more donor-recip

42 9%) had history of myocarditis diagnosed by endomyocardial biopsy (59%) and/or cardiac magnetic reso

43 hs, 64% occurred within 3 months of the last endomyocardial biopsy, 96% had normal biopsies, and the

44 ation relies on histopathological grading of endomyocardial biopsies according to International Socie

45 ter nucleic acids had been extracted from an endomyocardial biopsy, an explant, or autopsy samples, P

46 Endomyocardial biopsies and blood samples from 38 patien

47 METHODS AND Endomyocardial biopsies and blood samples were obtained

48 We reviewed the simultaneously obtained endomyocardial biopsies and intravascular ultrasound (IV

49 We evaluated PIMI in the first four weekly endomyocardial biopsies and/or autopsy myocardium from 1

50 AM and PM groups were defined based on endomyocardial biopsy and cardiac magnetic resonance fin

51 retrospectively identified who had undergone endomyocardial biopsy and cardiac MR at one institution

52 d clinically suspected myocarditis underwent endomyocardial biopsy and CMR at 1.5 Tesla.

53 Acute allograft rejection was diagnosed by endomyocardial biopsy and graded according to the Intern

54 disorder has led to the possible overuse of endomyocardial biopsy and immunosuppressive agents.

55 transplant recipients underwent simultaneous endomyocardial biopsy and intravascular ultrasound (IVUS

56 nts require more invasive procedures such as endomyocardial biopsy and may aid in reducing the number

57 ave myocarditis according to the findings on endomyocardial biopsy and the Dallas histopathological c

58 Rejection was diagnosed using endomyocardial biopsy and were graded according to stand

59 ant recipients who were referred for routine endomyocardial biopsy and/or surveillance coronary angio

60 with histologically proven amyloid (374 with endomyocardial biopsies) and 360 patients subsequently c

61 ranscriptional profiling was performed on 26 endomyocardial biopsies, and expression patterns were co

62 thy-associated gene-panel, echocardiography, endomyocardial biopsies, and Holter monitoring.

63 Annual coronary angiograms, serial endomyocardial biopsies, and serum cardiac troponin-T co

64 echocardiogram, right ventricular angiogram, endomyocardial biopsy, and 24-hour ambulatory ECG.

65 Repeat endomyocardial biopsies are frequently needed to diagnos

66 the major limitations, and currently, serial endomyocardial biopsies are required to diagnose rejecti

67 Cardiac magnetic resonance imaging or endomyocardial biopsy are required for definitive diagno

68 itivity or specificity needed to replace the endomyocardial biopsy as a diagnostic tool.

69 jection in humans might obviate the need for endomyocardial biopsy as well as improve the accuracy of

70 VEGF is expressed in normal human endomyocardial biopsies at low levels and is induced (sc

71 including TD imaging, along with transmural endomyocardial biopsy at the time of coronary bypass sur

72 sis of 196 consecutive patients referred for endomyocardial biopsy because of clinical suspicion of c

73 of patients with DCM, 99 patients underwent endomyocardial biopsies before CRT implantation, with hi

74 All underwent an endomyocardial biopsy before randomization, which reveal

75 We analyzed 169 sequential human endomyocardial biopsies by immunocytochemistry for infil

76 Endomyocardial biopsy can demonstrate fibro-fatty replac

77 In some patients, cardiac MRI and endomyocardial biopsy can help identify myocarditis, pre

78 that transcriptomic biomarkers from a single endomyocardial biopsy can improve the clinical detection

79 nological factors at the time of a low-grade endomyocardial biopsy can predict progression to high-gr

80 were also found to be clonally explanted in endomyocardial biopsies collected 17 and 21 mo earlier f

81 cular atheroma excised at endarterectomy and endomyocardial biopsies contained purely variant fibrino

82 schemic changes in early posttransplantation endomyocardial biopsies correlate with the later develop

83 criptomic signature, generated from a single endomyocardial biopsy, could serve as a novel prognostic

84 Among 74 patients with endomyocardial biopsy diagnosis of FD cardiomyopathy, 13

85 transplant recipients following inadvertent endomyocardial biopsy disruption of the tricuspid appara

86 GF) mRNA expression was determined in serial endomyocardial biopsies during the first year after tran

87 Endomyocardial biopsies (EMB) from heart failure (HF) pa

88 Multiple routine endomyocardial biopsies (EMB) remain the gold standard t

89 -CD68) and histopathologic criteria found on endomyocardial biopsies (EMB).

90 pathology were addressed: (a) Improvement of endomyocardial biopsy (EMB) accuracy for the diagnosis o

91 Endomyocardial biopsy (EMB) has a low sensitivity.

92 Endomyocardial biopsy (EMB) has an important role in det

93 diac magnetic resonance (CMR) mapping versus endomyocardial biopsy (EMB) has not been determined.

94 ration and frequency of routine surveillance endomyocardial biopsy (EMB) have been questioned in the

95 d many to question the yield of surveillance endomyocardial biopsy (EMB) in heart transplantation (HT

96 Endomyocardial biopsy (EMB) is a low risk procedure in a

97 The endomyocardial biopsy (EMB) is considered the gold stand

98 Endomyocardial biopsy (EMB) is often considered when the

99 ac transplantation, and regular surveillance endomyocardial biopsy (EMB) is required.

100 Endomyocardial biopsy (EMB) is the gold standard method

101 ue of the distinction between CS and IGCM on endomyocardial biopsy (EMB) is unknown.

102 tic resonance (CMR), cardiac biomarkers, and endomyocardial biopsy (EMB) results to predict left vent

103 Endomyocardial biopsy (EMB) screening represents the sta

104 Use of left ventricular (LV) endomyocardial biopsy (EMB) to investigate cardiomyopath

105 tients who had blood samples obtained during endomyocardial biopsy (EMB).

106 e evidence of antibody-mediated rejection by endomyocardial biopsy (EMB).

107 adult heart transplant (HTx) patients is an endomyocardial biopsy (EMB).

108 ons between genome-wide molecular changes in endomyocardial biopsies (EMBs) and plasma dd-cfDNA.

109 on after heart transplant (HT), surveillance endomyocardial biopsies (EMBs) are often continued for y

110 To determine the utility of surveillance endomyocardial biopsies (EMBs) during a 14-day OKT3 indu

111 e total Treg population, we examined Treg in endomyocardial biopsies (EMBs) of both patients who deve

112 lyzing digital pathology images from routine endomyocardial biopsies (EMBs) to develop a precision me

113 d for the presence of viral genome in serial endomyocardial biopsies (EMBs) using polymerase chain re

114 iagnostic System (MMDx) for heart transplant endomyocardial biopsies (EMBs).

115 ntitative evaluation of the extent of MVI in endomyocardial biopsies (EMBs).

116 ng (EVM) is a promising modality for guiding endomyocardial biopsies (EMBs).

117 After heart transplantation, endomyocardial biopsy (EMBx) is used to monitor for acut

118 nological factors at the time of a low-grade endomyocardial biopsy enables prospective stratification

119 ited utilization and the poor sensitivity of endomyocardial biopsies (especially for patchy diseases

120 Myocardial tissue from endomyocardial biopsy, explant, or autopsy was analyzed

121 Endomyocardial biopsies fibrosis did not relate to CRT r

122 Endomyocardial biopsy fibrosis was quantitatively measur

123 The authors indicate when to use endomyocardial biopsy for the diagnosis of cardiac amylo

124 ional research that influence the utility of endomyocardial biopsy for the management of inflammatory

125 Endomyocardial biopsies from 19 old patients with a dila

126 ir receptors CXCR3 and CCR5 was tested in 60 endomyocardial biopsies from 24 patients using quantitat

127 Right ventricular endomyocardial biopsies from 30 cases of allograft rejec

128 ern of vascular cardiac allograft rejection, endomyocardial biopsies from 344 heart transplant recipi

129 D We analyzed pretreatment and posttreatment endomyocardial biopsies from 58 Fabry patients enrolled

130 In 1320 endomyocardial biopsies from 645 patients previously stu

131 Autopsy specimens from 5 patients and endomyocardial biopsies from 7 patients were used for th

132 estigated in both cultured keratinocytes and endomyocardial biopsies from affected individuals.

133 the presence of acute cellular rejection in endomyocardial biopsies from cardiac transplant recipien

134 ve RT-PCR in RNA from right ventricular (RV) endomyocardial biopsies from intact nonfailing hearts, a

135 properties of mCSCs and vCSCs isolated from endomyocardial biopsies from patients with advanced hear

136 d (P=0.012) and 5.1-fold (P=0.038) higher in endomyocardial biopsies from patients with CVB3-positive

137 ntiated adult heart muscle cells, studies in endomyocardial biopsies from patients with dilated and i

138 luorescence, and immunoperoxidase studies of endomyocardial biopsies from such patients often reveal

139 echocardiograms, hemodynamic parameters, and endomyocardial biopsys from 137 patients with heart tran

140 Percentage of endomyocardial biopsies (grade 3a, 3b, and 4) with respe

141 For endomyocardial-biopsy grades 1B or 2, a positive lymphoc

142 Endomyocardial biopsy has defined rejection in clinical

143 The endomyocardial biopsy has defined the diagnosis of rejec

144 The endomyocardial biopsy has long been the preferred techni

145 res surrogate cardiac imaging biomarkers, as endomyocardial biopsy has relatively low yield, even wit

146 Endomyocardial biopsy has stood the test of time as a su

147 nce of significant rejection on the basis of endomyocardial biopsy histology.

148 N=2900 endomyocardial biopsy images were assigned a rejection g

149 erum samples were retrospectively matched to endomyocardial biopsies in 98 cardiac transplant recipie

150 Protocol endomyocardial biopsies in all three patients revealed n

151 Endomyocardial biopsies in those with elevated AT1R-Ab l

152 Findings were confirmed by endomyocardial biopsy in 64% (29 of 45) of participants.

153 he diagnosis, partly due to the low yield of endomyocardial biopsy in cardiac sarcoidosis.

154 ed recently as potential substitutes for the endomyocardial biopsy in detecting rejection.

155 nvasive test holds promise for replacing the endomyocardial biopsy in heart transplant recipients and

156 9 (terminal pathway), at the time of routine endomyocardial biopsy in heart transplant recipients.

157 uptake on bone scintigraphy and/or positive endomyocardial biopsy in the absence of monoclonal prote

158 This article reviews the current role of the endomyocardial biopsy in the management of patients foll

159 ression profiling or with the use of routine endomyocardial biopsies, in addition to clinical and ech

160 ve addressed important issues concerning the endomyocardial biopsy, including the reliability of the

161 The sensitivity of transvenous endomyocardial biopsy increased from 68% (19/28 patients

162 istic regression, odds of identifying ACR on endomyocardial biopsy increased with doubling of CXCL10

163 e DNA from the donor genome at times when an endomyocardial biopsy independently established the pres

164 n-fixed, paraffin-embedded right ventricular endomyocardial biopsies is diagnostic of immunopathologi

165 +) T cells and the CXCR3 ligand IP-10 within endomyocardial biopsies is strongly associated with acut

166 Percutaneous endomyocardial biopsy is a widely used and valuable proc

167 The endomyocardial biopsy is also limited by sub-optimal int

168 Endomyocardial biopsy is confirmatory for myocarditis, b

169 Endomyocardial biopsy is currently the standard method u

170 Risk of endomyocardial biopsy is highest in sick children with s

171 gnostic yield of cardiac sarcoidosis (CS) by endomyocardial biopsy is limited.

172 are often used as initial diagnostic tests, endomyocardial biopsy is required for definitive diagnos

173 Although endomyocardial biopsy is the criterion standard diagnost

174 Endomyocardial biopsy is the major method for detecting

175 Endomyocardial biopsy is the standard method of monitori

176 Endomyocardial biopsy is used routinely for diagnosing a

177 n the invasive and low-sensitivity nature of endomyocardial biopsy, its diagnostic focus shifted to a

178 Each sample was paired with an endomyocardial biopsy (<30 days).

179 Endomyocardial biopsy, lymphocyte-growth assays, and ant

180 Endomyocardial biopsy, mainly right ventricular, had a s

181 in pathologic processes, Egr-1 expression in endomyocardial biopsies may act as a surrogate marker of

182 The sensitivity of endomyocardial biopsy may be increased, especially in su

183 rranted to characterize patients with TCM by endomyocardial biopsy more clearly.

184 ntation has traditionally relied on numerous endomyocardial biopsies, most of which occur during the

185 ig), and their receptor CXCR3 in consecutive endomyocardial biopsies (n = 133) from human cardiac all

186 Antigen expression was detected on endomyocardial biopsies (n = 50) and spleen (n = 11) by

187 ion of VEGF by immunohistochemistry in human endomyocardial biopsies (n=101) from 10 cardiac transpla

188 We obtained left ventricular endomyocardial biopsies (n=12) for mRNA expression analy

189 ood mononuclear cells (n=24), plasma (n=27), endomyocardial biopsies (n=2), and cardiac tissue sample

190 uring subsequent cardiac surgery (n = 3) and endomyocardial biopsy (n = 1).

191 (n = 26), coronary angiography (n = 32), and endomyocardial biopsy (n = 32).

192 rdiac tissues obtained from autopsies (n=3), endomyocardial biopsy (n=1), or cardiac transplants (n=2

193 METHODS AND Endomyocardial biopsy NOD2 mRNA expression was higher in

194 of ATTR-CM without the need for confirmatory endomyocardial biopsies; observational studies indicate

195 ry deposition of C4d or C3d were detected in endomyocardial biopsies of 14 of the 33 patients.

196 observed an increase in MYOCD levels in the endomyocardial biopsies of DCM patients associated with

197 Egr-1 protein expression was analyzed in endomyocardial biopsies of different rejection grades by

198 PAR2 expression in endomyocardial biopsies of patients with nonischemic car

199 myocardial fibrosis has been detected in the endomyocardial biopsies of survivors.

200 ling of protein-coding genes and 754 miRs in endomyocardial biopsies of test cohorts was performed at

201 We performed endomyocardial biopsies of the RV side of the septum and

202 ology and sarcomere alterations described in endomyocardial biopsies of transplant patients with reje

203 Endomyocardial biopsy on postoperative day 56 showed fib

204 Nine episodes of CAVB occurred during endomyocardial biopsy or coronary angiography, and four

205 rol had antibody-mediated rejection (AMR) by endomyocardial biopsy (P<0.01).

206 There was a decrease in the use of endomyocardial biopsy (P=0.03) and an increase in the us

207 d RNA sequencing on right ventricular septal endomyocardial biopsies prospectively obtained from pati

208 ionship between MDR1/ABCB1 polymorphisms and endomyocardial biopsy-proven rejection (EBPR) determined

209 y correlated with inflammatory cell count on endomyocardial biopsy (r=0.56; P<0.05).

210 ere-derived cells (CDCs) isolated from human endomyocardial biopsies reduce infarct size and improve

211 Results were correlated with endomyocardial biopsy rejection grades.

212 Cardiac catheterization and endomyocardial biopsy remain the "gold standard" for dia

213 Endomyocardial biopsy remains the gold standard for in v

214 on was diagnosed through a review of routine endomyocardial biopsy reports.

215 ith cardiac biomarkers, cardiac imaging, and endomyocardial biopsy represent a pragmatic diagnostic a

216 etection of transplant rejection by repeated endomyocardial biopsy requires catheterization and entai

217 fraction to < or = 40%, and one because her endomyocardial biopsy result was grade 1.5.

218 The therapeutic and prognostic benefits of endomyocardial biopsy results have recently been demonst

219 Analysis of serial endomyocardial biopsies revealed that high levels of end

220 Endomyocardial biopsy revealed active myocarditis in 16

221 At postoperative day 50, the endomyocardial biopsy revealed damaged capillaries with

222 Endomyocardial biopsy revealed more advanced grade C and

223 Cardiac transcriptomic profiling of endomyocardial biopsies reveals a strong proinflammatory

224 mmunological and histological analyses of an endomyocardial biopsy sample are indicated when inflamma

225 in patients with new-onset HF from a single endomyocardial biopsy sample.

226 munohistochemical analysis of a conventional endomyocardial-biopsy sample appears to be a highly sens

227 , 101b, 21a) were compared with time-matched endomyocardial biopsy samples (n = 70) in 12 patients to

228 Endomyocardial biopsy samples and clinical data were col

229 The current study investigated endomyocardial biopsy samples from patients with TCM and

230 Levels of TSP-1 mRNA in endomyocardial biopsy samples of human cardiac allograft

231 Immunohistochemistry of endomyocardial biopsy samples revealed altered expressio

232 entification of infiltration and fibrosis in endomyocardial biopsy samples to assess transplant rejec

233 In cases of myocarditis (n=7), endomyocardial biopsy samples were analyzed by PCR and c

234 Serial LV endomyocardial biopsy samples were obtained at each echo

235 Serial LV endomyocardial biopsy samples were obtained to measure c

236 Matching endomyocardial biopsy samples were screened immunohistoc

237 Among a total of 350 endomyocardial biopsy samples, 180 were identified as id

238 tologic and immunofluorescence evaluation of endomyocardial biopsy samples, despite invasiveness and

239 nd arterial endothelial ICAM-1 expression in endomyocardial biopsy samples.

240 ulation of SA CMCs was isolated from porcine endomyocardial biopsy samples.

241 F) were correlated with clinical outcome and endomyocardial biopsy scores.

242 diac fibrosis was assessed histologically on endomyocardial biopsy sections.

243 Endomyocardial biopsy should be broadly and promptly use

244 Samples drawn <12 hours after endomyocardial biopsy showed high (0.40% [0.15%-1.21%])

245 and electroanatomical voltage mapping-guided endomyocardial biopsy showed low endocardial voltages an

246 Endomyocardial biopsy showed mononuclear infiltrates and

247 c right ventricular cardiomyopathy and of an endomyocardial biopsy showing fibro-fatty replacement co

248 The study cohort consisted of 2472 endomyocardial biopsy slides originating from three majo

249 lar rejection grading scheme for heart graft endomyocardial biopsy specimens (EMBs).

250 Standard morphological features of endomyocardial biopsy specimens do not necessarily corre

251 A total of 157 endomyocardial biopsy specimens from 26 patients with he

252 Three hundred sixteen serial endomyocardial biopsy specimens from 30 heart transplant

253 Endomyocardial biopsy specimens from 40 patients with pr

254 We studied endomyocardial biopsy specimens from 7 sex-mismatched (f

255 as is expressed on myocytes, we investigated endomyocardial biopsy specimens from cardiac transplant

256 okine and receptor gene expression in serial endomyocardial biopsy specimens from heart transplant pa

257 e-transcriptase polymerase chain reaction in endomyocardial biopsy specimens from human heart transpl

258 Serial sections of individual endomyocardial biopsy specimens from patients histologic

259 Percutaneous endomyocardial biopsy specimens grown in primary culture

260 In addition, studies of endomyocardial biopsy specimens have furthered our under

261 d percent fibrosis were determined in serial endomyocardial biopsy specimens obtained from 1 month up

262 Immunocytochemistry was performed on serial endomyocardial biopsy specimens to evaluate endothelial

263 Endomyocardial biopsy specimens were evaluated during th

264 to receive CDCs, autologous cells grown from endomyocardial biopsy specimens were infused into the in

265 ologous CDCs (12.5 to 25 x 10(6)) grown from endomyocardial biopsy specimens were infused via the int

266 B19V DNA and messenger RNA from endomyocardial biopsy specimens, bone marrow specimens,

267 the isolation of adult human stem cells from endomyocardial biopsy specimens.

268 expression was increased during rejection in endomyocardial biopsy specimens.

269 ass spectrometry-based proteomic analysis of endomyocardial biopsy specimens.

270 Endomyocardial-biopsy specimens were evaluated for evide

271 +/- standard deviation) consecutive routine endomyocardial biopsy surveillance visits during the fir

272 ere positive, concomitantly with a low-grade endomyocardial biopsy, the positive predictive value for

273 ications, the authors do not advocate use of endomyocardial biopsy to diagnose myocarditis in the set

274 icroscope (MMDx) system for heart transplant endomyocardial biopsies used expression of rejection-ass

275 Endomyocardial biopsy was conducted in 5 patients and re

276 including patients with ATTR-CA diagnosed by endomyocardial biopsy was conducted.

277 Gal-3 levels and inflammatory cell count on endomyocardial biopsy was observed in patients with iCMP

278 m each patient were examined for AECA and an endomyocardial biopsy was performed at regular intervals

279 Endomyocardial biopsy was performed in 9 of the 12 ARVD/

280 Endomyocardial biopsy was safe, and cardiac magnetic res

281 Serial cardiac monitoring, including endomyocardial biopsies, was performed.

282 A total of 240 heart transplant endomyocardial biopsies were assessed.

283 To determine whether ischemic changes in endomyocardial biopsies were associated with complement

284 A total of 132 blood specimens and endomyocardial biopsies were collected from 35 patients,

285 Endomyocardial biopsies were collected with a bioptome f

286 Serial endomyocardial biopsies were evaluated for cellular reje

287 Endomyocardial biopsies were evaluated within 2 weeks of

288 Porcine endomyocardial biopsies were harvested and plated as org

289 rom transplant recipients undergoing routine endomyocardial biopsies were included in an RNA sequenci

290 Autologous cardiospheres or CDCs grown from endomyocardial biopsies were injected through thoracotom

291 Plasma and endomyocardial biopsies were obtained from HFpEF (n=38),

292 gery (mean follow-up 8.3 months) when repeat endomyocardial biopsies were obtained to correlate trans

293 Serial radionuclide ventriculography and endomyocardial biopsies were performed at baseline, 3, a

294 acute myocarditis typically requires either endomyocardial biopsy (which is invasive) or cardiovascu

295 ognized at autopsy before the application of endomyocardial biopsy, which led to a histopathology-bas

296 methods for the detection of rejection, the endomyocardial biopsy will remain important in the manag

297 inical safety of any such approach, invasive endomyocardial biopsy will remain the gold standard.

298 tegory (1R) appears to have brought together endomyocardial biopsies with different underlying proces

299 eactivity was not detectable in four of five endomyocardial biopsies with normal histology.

300 ized that the transcriptome obtained from an endomyocardial biopsy would yield clinically relevant an